ELSEVIER

Clinica Chimica Acta 300 (2000) 219–220

www.elsevier.com/locate/clinchim

Author index

Volume 300 (2000)

Ali-Labib, R., see Eissa, S. **300**, 159
Álvarez, E., see Ruiz-Pesini, E. **300**, 97
Asa, S.L., see Magklara, A. **300**, 171
Awadallah, S., see Hamad, M. **300**, 75

Bellik, B., see Houzé, P. **300**, 181
Biddle, D.A., Datta, P., Wells, A., Dasgupta, A., Falsely elevated serum digitoxin concentrations due to cross-reactivity of water-extractable digitoxin-like immunoreactivity of Chinese medicine Chan SU: elimination of interference by use of a chemiluminescent assay **300**, 151
Bouro, F., see Houzé, P. **300**, 181
Bousquet, B., see Houzé, P. **300**, 181
Bozzi, A., see D'Alessandro, A.M. **300**, 119
Brguljan, P.M., see Cimerman, N. **300**, 83
Brisdelli, F., see D'Alessandro, A.M. **300**, 119
Brouet, J.C., see Houzé, P. **300**, 181

Chalmers, R.A., see Jones, M.G. **300**, 203
Chan, D.W., see Green, G.B. **300**, 57
Cheung, C.C., see Magklara, A. **300**, 171
Cimerman, N., Brguljan, P.M., Krašovec, M., Šuškovič, S., Kos, J., Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients **300**, 83
Cömlekci, A., see Kuralay, F. **300**, 43

D'Alessandro, A.M., Rinaldi, A.C., D'Andrea, G., Brisdelli, F., Di Ciccio, L., Di Giulio, A., Oratore, A., Bozzi, A., Evidences that zidovudine (AZT) could not be directly responsible for iron overload in AZT-treated patients: an in vitro study **300**, 119
D'Andrea, G., see D'Alessandro, A.M. **300**, 119
Dasgupta, A., see Biddle, D.A. **300**, 151
Datta, P., see Biddle, D.A. **300**, 151
Daxecker, H., see Heinschink, A. **300**, 23
Dehlinger, E., see Green, G.B. **300**, 57
De Iuliis, A., see Galzigna, L. **300**, 131
Deuther-Conrad, W., see Franke, S. **300**, 29
Di Ciccio, L., see D'Alessandro, A.M. **300**, 119
Di Giulio, A., see D'Alessandro, A.M. **300**, 119
Diamandis, E.P., see Magklara, A. **300**, 171
Diament, J., see Salazar, L.A. **300**, 139
Díez, C., see Ruiz-Pesini, E. **300**, 97

Eissa, S., Ali-Labib, R., Khalifa, A., Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC) **300**, 159
Elghetany, M.T., see Rao, L.V. **300**, 13
Enríquez, J.A., see Ruiz-Pesini, E. **300**, 97
Erwa, W., see Mangge, H. **300**, 195

Forti, N., see Salazar, L.A. **300**, 139
Franke, S., Niwa, T., Deuther-Conrad, W., Sommer, M., Hein, G., Stein, G., Immunochemical detection of imidazolone in uremia and rheumatoid arthritis **300**, 29

Gallistl, S., see Mangge, H. **300**, 195
Galzigna, L., De Iuliis, A., Zanatta, L., Enzymatic dopamine peroxidation in substantia nigra of human brain **300**, 131
Giannini, S.D., see Salazar, L.A. **300**, 139
Green, G.B., Dehlinger, E., McGrievey, T.S., Li, D.J., Jones, K.A., Kelen, G.D., Chan, D.W., CK-MB isoforms for early risk stratification of emergency department patients **300**, 57
Griesmacher, A., see Heinschink, A. **300**, 23

Hamad, M., Awadallah, S., Age group-associated variations in the pattern of Hp type distribution in Jordanians **300**, 75

PII: S0009-8981(00)00344-2

Hein, G., see Franke, S. **300**, 29
Heinschink, A., Raab, M., Daxecker, H., Griesmacher, A., Müller, M.M., In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes **300**, 23
Herrmann, J., see Mangge, H. **300**, 195
Hirata, M.H., see Salazar, L.A. **300**, 139
Hirata, R.D.C., see Salazar, L.A. **300**, 139
Houzé, P., Bellik, B., Brouet, J.C., Bouro, F., Bousquet, B., Comparison of urinary markers for bone resorption in multiple myeloma **300**, 181

Jones, K.A., see Green, G.B. **300**, 57
Jones, M.G., Chalmers, R.A., Artefacts in organic acid analysis: occurrence and origin of partially trimethylsilylated 3-hydroxy-3-methyl carboxylic acids **300**, 203

Kelen, G.D., see Green, G.B. **300**, 57
Khalifa, A., see Eissa, S. **300**, 159
Komosinska-Vassev, K., Olczyk, K., Kucharz, E.J., Marcisz, C., Winsz-Szczotka, K., Kotulska, A., Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy **300**, 107
Kos, J., see Cimerman, N. **300**, 83
Kotulska, A., see Komosinska-Vassev, K. **300**, 107
Krašovec, M., see Cimerman, N. **300**, 83
Kucharz, E.J., see Komosinska-Vassev, K. **300**, 107
Kuralay, F., Tokgöz, Z., Cömlekci, A., Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin **300**, 43

Lapeña, A.C., see Ruiz-Pesini, E. **300**, 97
Li, D.J., see Green, G.B. **300**, 57
Liebmann, P., see Mangge, H. **300**, 195
Lima, T.M., see Salazar, L.A. **300**, 139
López-Pérez, M.J., see Ruiz-Pesini, E. **300**, 97

Magklara, A., Cheung, C.C., Asa, S.L., Diamandis, E.P., Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland **300**, 171
Mangge, H., Liebmann, P., Tanil, H., Herrmann, J., Wagner, C., Gallistl, S., Schauenstein, K., Erwa, W., Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis **300**, 195
Marcisz, C., see Komosinska-Vassev, K. **300**, 107
McGrievey, T.S., see Green, G.B. **300**, 57
Müller, M.M., see Heinschink, A. **300**, 23

Niwa, T., see Franke, S. **300**, 29

Okorodudu, A.O., see Rao, L.V. **300**, 13
Olczyk, K., see Komosinska-Vassev, K. **300**, 107
Oratore, A., see D'Alessandro, A.M. **300**, 119

Patel, V.B., Richardson, P.J., Preedy, V.R., Inability of propranolol to prevent alcohol-induced reductions in cardiac protein synthesis in vivo **300**, 1
Petersen, J.R., see Rao, L.V. **300**, 13
Preedy, V.R., see Patel, V.B. **300**, 1

Raab, M., see Heinschink, A. **300**, 23
Rao, L.V., Okorodudu, A.O., Petersen, J.R., Elghetany, M.T., Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions **300**, 13
Richardson, P.J., see Patel, V.B. **300**, 1
Rinaldi, A.C., see D'Alessandro, A.M. **300**, 119
Ruiz-Pesini, E., Lapeña, A.C., Díez, C., Álvarez, E., Enríquez, J.A., López-Pérez, M.J., Seminal quality correlates with mitochondrial functionality **300**, 97

Salazar, L.A., Hirata, M.H., Giannini, S.D., Forti, N., Diament, J., Lima, T.M., Hirata, R.D.C., Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease **300**, 139
Schauenstein, K., see Mangge, H. **300**, 195
Sommer, M., see Franke, S. **300**, 29
Stein, G., see Franke, S. **300**, 29
Šuškovič, S., see Cimerman, N. **300**, 83

Tanil, H., see Mangge, H. **300**, 195
Tokgöz, Z., see Kuralay, F. **300**, 43
Tsuboi, I., Interleukin-1α antisense oligomer suppresses hepatocyte growth **300**, 213

Wagner, C., see Mangge, H. **300**, 195
Wells, A., see Biddle, D.A. **300**, 151
Winsz-Szczotka, K., see Komosinska-Vassev, K. **300**, 107

Zanatta, L., see Galzigna, L. **300**, 131

ELSEVIER

Clinica Chimica Acta 300 (2000) 221–224

www.elsevier.com/locate/clinchim

Subject index

Volume 300 (2000)

AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300**, 119

Activated partial thromboplastin time; Coagulation testing; Prothrombin time; Stability; Storage; Pre-transport temperature requirements **300**, 13

Activation markers; Mycophenolic acid; Cell cycle **300**, 23

Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; β_2-microglobulin; Chronic renal failure; Rheumatoid arthritis **300**, 29

Age group; Hp; Phenotype; Allele frequency; Jordan **300**, 75

Alcohol; Heart; Male Wistar rat; β-Blocker **300**, 1

Allele frequency; Hp; Phenotype; Age group; Jordan **300**, 75

Angiography; Candidate genes; Genetic polymorphism; Coronary artery disease; Atherosclerosis **300**, 139

Antioxidants; Graves' disease; Lipid peroxidation; Protein oxidation **300**, 107

Antisense oligome; Interleukin-1α; Hepatocyte **300**, 213

Artefacts; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC–MS; Trimethylsilylation **300**, 203

Asthma; Cystatin C; Creatinine; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83

Atherosclerosis; Candidate genes; Genetic polymorphism; Coronary artery disease; Angiography **300**, 139

Bisphosphonates; Carboxyterminal telopeptide; Total pyridinolines; Multiple myeloma **300**, 181

Bladder cancer; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; SCC; Schistosomiasis. **300**, 159

β-Blocker; Heart; Alcohol; Male Wistar rat **300**, 1

CK-MB; Isoforms; Emergency department; Ischemia; Risk; Chest pain **300**, 57

Calcein; AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells **300**, 119

Candidate genes; Genetic polymorphism; Coronary artery disease; Atherosclerosis; Angiography **300**, 139

Carbohydrate antigen-125; Pleural effusion; Carbohydrate antigen-19.9; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43

Carbohydrate antigen-19.9; Pleural effusion; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43

PII: S0009-8981(00)00345-4

Carboxyterminal telopeptide; Total pyridinolines; Multiple myeloma; Bisphosphonates **300**, 181

Cell cycle; Mycophenolic acid; Activation markers **300**, 23

Chan SU; Digitoxin; Fluorescence polarization immunoassay; Chemiluminescent immunoassay **300**, 151

Chemiluminescent immunoassay; Digitoxin; Chan SU; Fluorescence polarization immunoassay **300**, 151

Chest pain; CK-MB; Isoforms; Emergency department; Ischemia; Risk **300**, 57

Chronic renal failure; Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; β_2-microglobulin; Rheumatoid arthritis **300**, 29

Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Stability; Storage; Pre-transport temperature requirements **300**, 13

Coronary artery disease; Candidate genes; Genetic polymorphism; Atherosclerosis; Angiography **300**, 139

Creatinine; Asthma; Cystatin C; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83

Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; Bladder cancer; SCC; Schistosomiasis. **300**, 159

Cyclosporin A; Asthma; Cystatin C; Creatinine; Serum; 24-h variations; Methylprednisolone **300**, 83

Cystatin C; Asthma; Creatinine; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83

Cystatin C; Prolonged RA; Early renal damage; Diagnosis **300**, 195

3-Deoxyglucosone; Advanced glycation end-product; Imidazolone; β_2-microglobulin; Chronic renal failure; Rheumatoid arthritis **300**, 29

Diagnosis; Prolonged RA; Early renal damage; Cystatin C **300**, 195

Digitoxin; Chan SU; Fluorescence polarization immunoassay; Chemiluminescent immunoassay **300**, 151

Dopamine; Substantia nigra; Parkinson's disease; Dopaminochrome; Peroxidase; Melanin; Neuroblastoma cells **300**, 131

Dopaminochrome; Substantia nigra; Parkinson's disease; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300**, 131

Early renal damage; Prolonged RA; Diagnosis; Cystatin C **300**, 195

Emergency department; CK-MB; Isoforms; Ischemia; Risk; Chest pain **300**, 57

Ferritin; Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen **300**, 43

Fluorescence polarization immunoassay; Digitoxin; Chan SU; Chemiluminescent immunoassay **300**, 151

GC–MS; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; Trimethylsilylation; Artefacts **300**, 203

Gene expression; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA **300**, 171

Genetic polymorphism; Candidate genes; Coronary artery disease; Atherosclerosis; Angiography **300**, 139

Graves' disease; Lipid peroxidation; Protein oxidation; Antioxidants **300**, 107

Heart; Alcohol; Male Wistar rat; β-Blocker **300**, 1

Hepatocyte; Interleukin-1α; Antisense oligome **300**, 213

Hp; Phenotype; Allele frequency; Age group; Jordan **300**, 75

Human glandular kallikrein 2 (hK2); Prostate-specific antigen (PSA); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300**, 171

3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC–MS; Trimethylsilylation; Artefacts **300**, 203

3-Hydroxy-3-methylglutaryl CoA lyase deficiency; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; GC–MS; Trimethylsilylation; Artefacts **300**, 203

3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC–MS; Trimethylsilylation; Artefacts **300**, 203

Imidazolone; Advanced glycation end-product; 3-Deoxyglucosone; β_2-microglobulin; Chronic renal failure; Rheumatoid arthritis **300**, 29

Interleukin-1α; Antisense oligome; Hepatocyte **300**, 213

Iron chelation; AZT; Zidovudine; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300**, 119

Iron overload; AZT; Zidovudine; Iron chelation; Transferrin; Transferrin receptor; K562 cells; Calcein **300**, 119

Ischemia; CK-MB; Isoforms; Emergency department; Risk; Chest pain **300**, 57

Isoforms; CK-MB; Emergency department; Ischemia; Risk; Chest pain **300**, 57

Jordan; Hp; Phenotype; Allele frequency; Age group **300**, 75

K562 cells; AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; Calcein **300**, 119

Kallikreins; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300**, 171

Lipid peroxidation; Graves' disease; Protein oxidation; Antioxidants **300**, 107

Male Wistar rat; Heart; Alcohol; β-Blocker **300**, 1

Melanin; Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Neuroblastoma cells **300**, 131

Methylprednisolone; Asthma; Cystatin C; Creatinine; Serum; 24-h variations; Cyclosporin A **300**, 83

β_2-microglobulin; Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; Chronic renal failure; Rheumatoid arthritis **300**, 29

Mitochondria; Oligozoospermia; OXPHOS; Spermatogenesis; Spermatozoa **300**, 97

Mucinous-carcinoma-associated antigen; Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Ferritin **300**, 43

Multiple myeloma; Carboxyterminal telopeptide; Total pyridinolines; Bisphosphonates **300**, 181

Mycophenolic acid; Activation markers; Cell cycle **300**, 23

Neuroblastoma cells; Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Melanin **300**, 131

Neuron specific enolase; Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43

Non-prostatic PSA; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Gene expression **300**, 171

OXPHOS; Mitochondria; Oligozoospermia; Spermatogenesis; Spermatozoa **300**, 97

Oligozoospermia; Mitochondria; OXPHOS; Spermatogenesis; Spermatozoa **300**, 97

p15; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p16; Bladder cancer; SCC; Schistosomiasis. **300**, 159

p16; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; Bladder cancer; SCC; Schistosomiasis. **300**, 159

Parkinson's disease; Substantia nigra; Dopaminochrome; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300**, 131

Peroxidase; Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Melanin; Neuroblastoma cells **300**, 131

Phenotype; Hp; Allele frequency; Age group; Jordan **300**, 75

Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43

Pre-transport temperature requirements; Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Stability; Storage **300**, 13

Prolonged RA; Early renal damage; Diagnosis; Cystatin C **300**, 195

Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300**, 171

Protein oxidation; Graves' disease; Lipid peroxidation; Antioxidants **300**, 107

Prothrombin time; Coagulation testing; Activated partial thromboplastin time; Stability; Storage; Pre-transport temperature requirements **300**, 13

Rheumatoid arthritis; Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; β_2-microglobulin; Chronic renal failure **300**, 29

Risk; CK-MB; Isoforms; Emergency department; Ischemia; Chest pain **300**, 57

SCC; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; Bladder cancer; Schistosomiasis. **300**, 159

Schistosomiasis; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; Bladder cancer; SCC **300**, 159

Serum; Asthma; Cystatin C; Creatinine; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83

Spermatogenesis; Mitochondria; Oligozoospermia; OXPHOS; Spermatozoa **300**, 97

Spermatozoa; Mitochondria; Oligozoospermia; OXPHOS; Spermatogenesis **300**, 97

Stability; Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Storage; Pre-transport temperature requirements **300**, 13

Storage; Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Stability; Pre-transport temperature requirements **300**, 13

Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300**, 131

Thyroid cancer; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Non-prostatic PSA; Gene expression **300**, 171

Thyroid; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid cancer; Non-prostatic PSA; Gene expression **300**, 171

Total pyridinolines; Carboxyterminal telopeptide; Multiple myeloma; Bisphosphonates **300**, 181

Transferrin receptor; AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; K562 cells; Calcein **300**, 119

Transferrin; AZT; Zidovudine; Iron chelation; Iron overload; Transferrin receptor; K562 cells; Calcein **300**, 119

Trimethylsilylation; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC–MS; Artefacts **300**, 203

Tumor suppressor gene; Cyclin dependent kinase inhibitors; p15; p16; Bladder cancer; SCC; Schistosomiasis. **300**, 159

24-h variations; Asthma; Cystatin C; Creatinine; Serum; Cyclosporin A; Methylprednisolone **300**, 83

Zidovudine; AZT; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300**, 119